#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Bone marrow disorder Leukaemia Bladder cancer Ovarian cancer stage III Chronic hepatitis B Cutaneous T-cell lymphoma stage II Hodgkin's disease refractory Pericarditis Immune-mediated renal disorder Adrenoleukodystrophy Anal cancer recurrent Chondrosarcoma Chondrodystrophy Ovarian epithelial cancer Primary hyperoxaluria More trials…

    Learn about Rare Diseases

    Marfan’s syndrome – Trials in Disease Acquired haemophilia – Life with Disease Piriformis syndrome – Trials in Disease Osteosarcoma recurrent – Treatment Shprintzen-Goldberg syndrome – Life with Disease Urea cycle disorder – Trials in Disease Andersen-Tawil syndrome – Trials in Disease Bronchiolitis obliterans syndrome – Trials in Disease Antisynthetase syndrome – Treatment Hereditary hypophosphataemic rickets – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sotalol Codeine Phosphate Danicamtiv Sodium Chloride Solution 0.9% Treg02 Nicotinamide Cefazolin Sodium Iti-1284 Ribonucleic Acid Fosfomycin VALACICLOVIR HYDROCHLORIDE Ciclosporin Imatinib Rgx-202 L-Glutamic Acid Simeticone Lovo-B Odm-208 Bezafibrate RIVASTIGMINE More therapies…

    Learn about Your Condition

    Oral herpes Mitochondrial myopathy Leiomyosarcoma Type V hyperlipidaemia Embolism venous Coeliac disease Glomerulonephritis membranous Inclusion body myositis Radicular pain Pulmonary sarcoidosis Hypotransferrinaemia Diphtheria Fatty acid oxidation disorder Insomnia Infectious pleural effusion More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Provita Poliklinika Sp. z o.o.

Provita Poliklinika Sp. z o.o.

Blkgfswbven 1 Ldg 2pem Wotqwry 0paoxed Pnisoz

Want to learn more about this study or check if you can participate? Contact us.

  • Long-term safety and effectiveness study of ritlecitinib in children with severe alopecia areata who completed previous trials B7981027 or B7981031

    Recruiting

    3 1
    Investigated Diseases:
    • Alopecia areata
    Czechia France Italy Poland Spain

  • Study of RO7837195 injection compared to placebo to treat moderate to severe ulcerative colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • RO7837195
    Czechia France Germany Italy Poland

  • Study on Cytisine for Quitting Nicotine E-Cigarettes and Tobacco in Motivated Individuals

    Recruiting

    3 1 1
    Investigated Drugs:
    • Cytisine
    Poland

  • Study of IMG-007 injection to treat moderate to severe atopic dermatitis in adults

    Not yet recruiting

    2 1
    Investigated Drugs:
    • Img-007
    Czechia Germany Hungary Poland Spain

  • A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Cardiovascular disorder
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Bulgaria Denmark France Germany Ireland Italy +3

  • Study of ritlecitinib for treating severe alopecia areata in children aged 6 to under 12 years

    Not recruiting

    3 1
    Czechia France Italy Poland Spain

  • Study of Tibulizumab to Treat Adults with Hidradenitis Suppurativa

    Not recruiting

    2 1
    Investigated Diseases:
    • Hidradenitis
    Germany Hungary Poland Spain

  • Study on the Safety and Immune Response of MenABCWY Vaccine and Drug Combination in Healthy Infants with Meningococcal Infections

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • GSKVX000000017986
    • HUMAN ROTAVIRUS RIX4414 STRAIN (LIVE ATTENUATED) PRODUCED ON VERO CELLS
    • MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 PROTEIN
    Germany Poland Spain

  • Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE)
    • Neisseria Meningitidis, Serogroup C, Polysaccharide, Conjugated To Tetanus Toxoid
    • RNMB1
    Czechia Denmark Finland Germany Poland Spain

  • Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Pneumococcal Polysaccharide Serotype 1
    • Pneumococcal Polysaccharide Serotype 10A
    • Pneumococcal Polysaccharide Serotype 11A
    Belgium Czechia Estonia Finland Germany Greece +3
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!